Liệu pháp kháng virus retro cho bệnh nhân chưa điều trị: Một tổng quan về tài liệu gần đây và các hướng dẫn cập nhật

AIDS Epidemic Update 2007. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO); 2007. Available at http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf. Accessed April 2009. Bhaskaran K, Hamouda O, Sannes M, et al.: Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008, 300:51–59. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: Department of Health and Human Services; 2008:1–139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 2009. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al.: Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008, 197:867–870. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, et al.: Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008, 197:1133–1144. Benhamou Y, Fleury H, Trimoulet P, et al.: Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006, 43:548–555. Hammer SM, Eron JJ Jr, Reiss P, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008, 300:555–570. Kitahata MM, Gange SJ, Abraham AG: Effect of early versus deferred antiretroviral therapy for HIV on survival. Available at http://content.nejm.org/cgi/content/abstract/360/18/1815. Accessed April 2009. Sullivan P, Kayitenkore K, Chomba E, et al.: Reduction of HIV transmission risk and high risk sex while prescribed ART: Results from discordant couples in Rwanda and Zambia [abstract 52bLB]. Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montréal, Canada; February 8–11, 2009. Granich RM, Gilks CF, Dye C, et al.: Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009, 373:48–57. Lichtenstein KA, Armon C, Buchacz K, et al.: Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr 2008, 47:27–35. Zolopa A, Andersen J, Komarow L, et al.; ACTG A5164 Study Team: Immediate vs deferred ART in the setting of acute AIDS-related opportunistic infection: final results of a randomized strategy trial, ACTG A5164 [abstract 142]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008. Adult Prevention and Treatment of Opportunistic Infections Guidelines Working Group: Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Bethesda, MD: Department of Health and Human Services; 2008:1–289. Available at http://aidsinfo.nih.gov/contentfiles/Adult_OI.pdf. Accessed April 2009. Abdool Karim S, Naidoo K, Grobler A, et al.: Initiating ART during TB treatment significantly increases survival: results of a randomized controlled clinical trial in TB/HIV-co-infected patients in South Africa [abstract 36a]. Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montréal, Canada; February 8–11, 2009. Delfraissy JF, Flandre P, Delaugerre C, et al.: Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008, 22:385–393. Ribaudo HJ, Kuritzkes DR, Gulick RM: A comparison of three initial antiretroviral AIDS regimens. N Engl J Med 2007, 357:1056–1057. Riddler SA, Haubrich R, DiRienzo AG, et al.: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008, 358:2095–2106. Nachega JB, Hislop M, Dowdy DW, et al.: Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in southern African adults. AIDS 2008, 22:2117–2125. van Leth F, Phanuphak P, Ruxrungtham K, et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 2004, 363:1253–1263. Clifford DB, Evans S, Yang Y, et al.: Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005, 143:714–721. Crane HM, Van Rompaey SE, Kitahata MM: Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine. AIDS Patient Care STDS 2007, 21:920–929. Viramune (nevirapine) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2009. Bannister WP, Ruiz L, Cozzi-Lepri A, et al.: Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS 2008, 22:367–376. Lapadula G, Calabresi A, Castelnuovo F, et al.: Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Antivir Ther 2008, 13:601–605. Molina JM: Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs 2008, 68:567–578. Molina JM, Andrade-Villanueva J, Echevarria J, et al.: Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008, 372:646–655. Molina J, Andrade-Villanueva J, Echevarria J, et al.: CASTLE: atazanavir-ritonavir vs lopinavir-ritonavir in antiretroviral-naive HIV-1 infected patients: 96 week efficacy and safety [abstract H-1250d]. Program and abstracts of the 48th ICAAC/46th IDSA. Washington DC; October 25–28, 2008. Moyle G, Girard J, Andrade J, et al.: Continuation of BID boosted PI vs. switch to once-daily ATV/RTV for the management of lipodystrophy: 48-week primary analysis of the 96-week multicenter, open-label, randomized, prospective ReAL study [abstract A-072-0080-04171]. Presented at the 17th International AIDS Conference. Mexico City, Mexico; August 3–8, 2008. Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB: Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration’s adverse event reporting system. AIDS 2007, 21:1215–1218. Reyataz (atazanavir) [package insert]. New York City: Bristol-Myers Squibb Company; 2009. Ortiz R, DeJesus E, Khanlou H, et al.: Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008, 22:1389–1397. Mills A, Nelson M, Jayaweera D, et al.: ARTEMIS: efficacy and safety of darunavir/ritonavir (DRV/r) 800/100 mg once-daily vs lopinavir/ritonavir (LPV/r) in treatment-naive, HIV-1-infected patients at 96 wks [abstract H-1250c]. Program and abstracts of the 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington DC; October 25–28, 2008. Eron J Jr, Yeni P, Gathe J Jr, et al.: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006, 368:476–482. Walmsley S, Avihingsanon A, Slim J, et al.: Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009, 50:367–374. Arribas JR, Pozniak AL, Gallant JE, et al.: Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatmentnaive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008, 47:74–78. van Griensven J, Zachariah R, Rasschaert F, et al.: Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir. Trans R Soc Trop Med Hyg 2008 (E-pub ahead of print). Santos SA, Uriel AJ, Park JS, et al.: Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. Eur J Gastroenterol Hepatol 2006, 18:1247–1253. Viread (tenofovir disoproxil fumarate) [package insert]. Foster City, CA: Gilead Sciences; 2009. Smith KY, Fine DM, Patel P, et al.: Similarity in efficacy and safety of abacavir/lamivudine (ABC/3TC) compared to tenofovir/emtricitabine (TDF/FTC) in combination with QD lopinavir/ritonavir (LPV/r) over 96 weeks in the HEAT study [abstract LBPE1138]. Presented at the 17th International AIDS Conference. Mexico City, Mexico; August 3–8, 2008. Sax P, Tierney C, Collier A, et al.: ACTG 5202: Shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naïe subjects with screening HIV RNA 100,000 c/mL [abstract THAB0303]. Presented at the 17th International AIDS Conference. Mexico City, Mexico; August 3–8, 2008. Panel on Antiretroviral Guidelines for Adult and Adolescents: DHHS Adults and Adolescents Antiretroviral Treatment Guidelines Panel’s Communication Regarding Abacavir–April 4, 2008. Available at http://aidsinfo.nih.gov/contentfiles/ABCComm.pdf. Accessed April 2009. Sabin C, Worm S, Weber R, et al.: Do thymidine analogues, abacavir, didanosine and lamivudine contribute to the risk of myocardial infarction? The D:A:D study. Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008. Lundgren J, Reiss P, Worm S, et al.: Risk of myocardial infarction with exposure to specific ARV from the PI, NNRTI, and NRTI drug classes: the D:A:D study [abstract 44LB]. Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montréal, Canada; February 8–11, 2009. Lundgren J, Neuhaus J, Babiker A, et al.: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the SMART study [abstract THAB0305]. Presented at the 17th International AIDS Conference. Mexico City, Mexico; August 3–8, 2008. Lang S, Mary-Krause M, Cotte L, et al.: Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4 [abstract 43LB]. Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montréal, Canada; February 8–11, 2009. Benson C, Ribaudo H, Zheng E; the ACTG A5001/ALLRT Protocol Team: No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001 [abstract 721]. Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montréal, Canada; February 8–11, 2009. Heera J, Saag M, Ive P, et al.: Virological correlates associated with treatment failure at week 48 in the phase 3 study of maraviroc in treatment-naive patients [abstract 40LB]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3–6, 2008. Saag M, Heera J, Goodrich J, et al.: Reanalysis of the MERIT study with the enhanced profile assay [abstract H-1232a]. Program and abstracts of the 48th ICAAC/46th IDSA. Washington DC; October 25–28, 2008. Lennox J, DeJesus E, Lazzarin A, et al.: STARTMRK, a phase III study of the safety and efficacy of raltegravir (RAL)-based vs efavirenz (EFV)-based combination therapy in treatment-naive HIV-infected patients [abstract H-896a]. Program and abstracts of the 48th ICAAC/46th IDSA. Washington DC; October 25–28, 2008.